(LH) Laboratory of America - Ratings and Ratios
Lab Tests, Genetic Testing, Diagnostic Services, Pathology, Wellness Programs
LH EPS (Earnings per Share)
LH Revenue
Description: LH Laboratory of America
Labcorp Holdings Inc. is a leading provider of laboratory services, operating through two main segments: Diagnostics Laboratories and Biopharma Laboratory Services. The company offers a wide range of tests and specialty testing services, including gene-based and esoteric testing, advanced disease-specific tests, and health and wellness services to various clients, including pharmaceutical companies, managed care organizations, and patients.
From a business perspective, Labcorps revenue streams are diversified across various sectors, including pharmaceutical and biotechnology companies, medical device manufacturers, and healthcare providers. The companys services also cater to employers, governments, and consumers directly. Key performance indicators (KPIs) to watch include revenue growth, segment-wise revenue contribution, and the companys ability to expand its test menu and services, particularly in the areas of genetic and esoteric testing.
Labcorps competitive edge lies in its comprehensive test offerings, advanced technology, and integrated services that span from specimen collection to complex diagnostic testing. The companys online and mobile applications enhance patient engagement and streamline processes for providers and payers. To gauge the companys financial health and operational efficiency, key metrics include operating margins, return on equity (RoE) of 8.98%, and the price-to-earnings (P/E) ratio of 30.21, indicating the markets expectations for future growth.
Strategically, Labcorp is well-positioned in the growing diagnostics market, driven by an aging population, increasing prevalence of chronic diseases, and advancements in genetic and precision medicine. The companys expansion into new markets, partnerships, and acquisitions will be critical in driving future growth. Monitoring Labcorps capital allocation, including its investments in research and development, marketing efforts, and potential mergers and acquisitions, will be essential in assessing its long-term prospects.
LH Stock Overview
| Market Cap in USD | 22,872m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 1990-03-29 |
LH Stock Ratings
| Growth Rating | 74.8% |
| Fundamental | 53.3% |
| Dividend Rating | 40.6% |
| Return 12m vs S&P 500 | 3.77% |
| Analyst Rating | 4.45 of 5 |
LH Dividends
| Dividend Yield 12m | 1.11% |
| Yield on Cost 5y | 1.90% |
| Annual Growth 5y | 15.77% |
| Payout Consistency | 17.4% |
| Payout Ratio | 19.0% |
LH Growth Ratios
| Growth Correlation 3m | 80.4% |
| Growth Correlation 12m | 81.8% |
| Growth Correlation 5y | 39.4% |
| CAGR 5y | 16.22% |
| CAGR/Max DD 3y | 0.93 |
| CAGR/Mean DD 3y | 3.14 |
| Sharpe Ratio 12m | 0.62 |
| Alpha | 0.08 |
| Beta | 0.810 |
| Volatility | 20.87% |
| Current Volume | 399.6k |
| Average Volume 20d | 399.6k |
| Stop Loss | 267.7 (-3%) |
| Signal | 0.64 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (763.4m TTM) > 0 and > 6% of Revenue (6% = 809.0m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 1.89pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.16% (prev -3.95%; Δ 14.11pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 1.69b > Net Income 763.4m (YES >=105%, WARN >=100%) |
| Net Debt (5.90b) to EBITDA (1.87b) ratio: 3.15 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (84.1m) change vs 12m ago -0.24% (target <= -2.0% for YES) |
| Gross Margin 28.14% (prev 27.02%; Δ 1.13pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 77.56% (prev 74.72%; Δ 2.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.29 (EBITDA TTM 1.87b / Interest Expense TTM 226.9m) >= 6 (WARN >= 3) |
Altman Z'' 3.43
| (A) 0.08 = (Total Current Assets 4.09b - Total Current Liabilities 2.72b) / Total Assets 18.06b |
| (B) 0.47 = Retained Earnings (Balance) 8.50b / Total Assets 18.06b |
| (C) 0.07 = EBIT TTM 1.20b / Avg Total Assets 17.39b |
| (D) 0.89 = Book Value of Equity 8.47b / Total Liabilities 9.57b |
| Total Rating: 3.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 53.32
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 4.51% = 2.25 |
| 3. FCF Margin 9.36% = 2.34 |
| 4. Debt/Equity 0.68 = 2.27 |
| 5. Debt/Ebitda 3.08 = -1.88 |
| 6. ROIC - WACC (= -0.81)% = -1.01 |
| 7. RoE 9.25% = 0.77 |
| 8. Rev. Trend -22.82% = -1.71 |
| 9. EPS Trend -24.46% = -1.22 |
What is the price of LH shares?
Over the past week, the price has changed by +1.15%, over one month by +2.33%, over three months by +6.68% and over the past year by +23.00%.
Is Laboratory of America a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LH is around 275.37 USD . This means that LH is currently overvalued and has a potential downside of -0.25%.
Is LH a buy, sell or hold?
- Strong Buy: 13
- Buy: 3
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 293.8 | 6.4% |
| Analysts Target Price | 293.8 | 6.4% |
| ValueRay Target Price | 303.8 | 10.1% |
Last update: 2025-09-06 04:42
LH Fundamental Data Overview
CCE Cash And Equivalents = 647.3m USD (last quarter)
P/E Trailing = 30.2119
P/E Forward = 15.5521
P/S = 1.6962
P/B = 2.6994
P/EG = 0.9311
Beta = 0.827
Revenue TTM = 13.48b USD
EBIT TTM = 1.20b USD
EBITDA TTM = 1.87b USD
Long Term Debt = 5.08b USD (from longTermDebt, last quarter)
Short Term Debt = 690.0m USD (from shortTermDebt, last quarter)
Debt = 5.77b USD (Calculated: Short Term 690.0m + Long Term 5.08b)
Net Debt = 5.90b USD (from netDebt column, last quarter)
Enterprise Value = 27.99b USD (22.87b + Debt 5.77b - CCE 647.3m)
Interest Coverage Ratio = 5.29 (Ebit TTM 1.20b / Interest Expense TTM 226.9m)
FCF Yield = 4.51% (FCF TTM 1.26b / Enterprise Value 27.99b)
FCF Margin = 9.36% (FCF TTM 1.26b / Revenue TTM 13.48b)
Net Margin = 5.66% (Net Income TTM 763.4m / Revenue TTM 13.48b)
Gross Margin = 28.14% ((Revenue TTM 13.48b - Cost of Revenue TTM 9.69b) / Revenue TTM)
Tobins Q-Ratio = 3.30 (Enterprise Value 27.99b / Book Value Of Equity 8.47b)
Interest Expense / Debt = 0.99% (Interest Expense 57.1m / Debt 5.77b)
Taxrate = 22.14% (212.4m / 959.5m)
NOPAT = 935.3m (EBIT 1.20b * (1 - 22.14%))
Current Ratio = 1.50 (Total Current Assets 4.09b / Total Current Liabilities 2.72b)
Debt / Equity = 0.68 (Debt 5.77b / last Quarter total Stockholder Equity 8.47b)
Debt / EBITDA = 3.08 (Net Debt 5.90b / EBITDA 1.87b)
Debt / FCF = 4.57 (Debt 5.77b / FCF TTM 1.26b)
Total Stockholder Equity = 8.25b (last 4 quarters mean)
RoA = 4.23% (Net Income 763.4m, Total Assets 18.06b )
RoE = 9.25% (Net Income TTM 763.4m / Total Stockholder Equity 8.25b)
RoCE = 9.01% (Ebit 1.20b / (Equity 8.25b + L.T.Debt 5.08b))
RoIC = 6.54% (NOPAT 935.3m / Invested Capital 14.31b)
WACC = 7.34% (E(22.87b)/V(28.64b) * Re(9.0%)) + (D(5.77b)/V(28.64b) * Rd(0.99%) * (1-Tc(0.22)))
Shares Correlation 3-Years: -90.67 | Cagr: -0.68%
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 68.62% ; FCFE base≈1.10b ; Y1≈796.5m ; Y5≈444.7m
Fair Price DCF = 87.02 (DCF Value 7.23b / Shares Outstanding 83.1m; 5y FCF grow -32.37% → 3.0% )
EPS Correlation: -24.46 | EPS CAGR: -2.62% | SUE: 2.13 | # QB: 2
Revenue Correlation: -22.82 | Revenue CAGR: -0.80% | SUE: 0.66 | # QB: 0
Additional Sources for LH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle